More harm than good? Potential benefits and unintended consequences associated with screening asymptomatic hospital admissions for severe acute respiratory syndrome coronavirus 2

Maria M. Torres-Teran MD, Maria E. Navas MD, Nataliya M. Kachaluba MS, Josh M. Meyer BS and Curtis J. Donskey MD

1Research Service, Louis Stokes Cleveland Veterans’ Affairs (VA) Medical Center, Cleveland, Ohio, 2Pathology and Laboratory Medicine Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, 3Geriatric Research, Education, and Clinical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio and 4Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio

To the Editor—During the coronavirus disease 2019 (COVID-19) pandemic, screening of asymptomatic patients for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the time of healthcare facility admission has often been used in an effort to reduce the risk of nosocomial transmission. However, the Society for Healthcare Epidemiology of America recently recommended against routine use of asymptomatic screening in healthcare facilities, including admission screening. Such testing is of unclear benefit when other control measures are in place and may result in unintended adverse consequences, including delays in medical care and unnecessary isolation and treatment of non-infectious patients.

In Veterans’ Affairs (VA) hospitals, it is recommended that all new admissions be screened for SARS-CoV-2 using a polymerase chain reaction (PCR) test. At this stage of the pandemic, PCR screening can be problematic because tests often remain positive for months after COVID-19, and undiagnosed infections are not uncommon. The cycle threshold (Ct) of the PCR test can be useful in assessing whether asymptomatic patients are infectious because high Ct values, which correlate with low viral burden, suggest a remote infection. In previous studies, many asymptomatic patients with positive PCR tests have been deemed noninfectious based on clinical presentation, serology, and high Ct value. Here, we conducted a retrospective study to evaluate the potential benefits and adverse consequences associated with screening asymptomatic patients being admitted to a VA hospital.

The Cleveland VA Medical Center’s Research and Development Committee determined that the study was a nonresearch, quality-improvement project not requiring approval from the institutional review board. Between September 1, 2022, and January 31, 2023, we obtained the Ct values of all patients testing positive for SARS-CoV-2 on admission except those with prior COVID-19 within 90 days. The Xpert Xpress CoV-2 plus assay (Cepheid) was used for testing. Ct values were not provided in the medical record but were available to infectious diseases providers upon request. Medical records and infection control databases were reviewed to obtain information on symptoms, prior COVID-19 diagnosis, test results for COVID-19, treatment and isolation for COVID-19, and suspected transmission based on contact tracing investigations.

Patients were deemed noninfectious if the admission sample and any additional samples collected within 3 days had a Ct value >35, antigen testing (if completed) was negative, and no symptoms consistent with COVID-19 developed during the hospital admission. The Ct cutoff of 35 was chosen based on evidence that positive SARS-CoV-2 cultures, a surrogate for infectiousness, are infrequent for samples with Ct values >35. The Ct result for the nucleocapsid (N2) target was used; if the N2 target was not detected, the highest Ct value reported for the envelope (E) or RNA-dependent RNA polymerase (RdRP) targets was used. Of 2,794 admissions during the study, 129 (4.6%) tested positive by PCR; 54 (41.9%) were asymptomatic, 9 (7.0%) were symptomatic, and 66 (51.2%) were symptomatic. Overall, 2.3% of hospital admissions (63 of 2,794) had positive PCR tests and were asymptomatic or presymptomatic. The mean Ct values for the asymptomatic, symptomatic, and presymptomatic patients were 35.9 (range, 15.0–44.5), 23.9 (range, 18.1–37.0), and 22.0 (range, 11.7–40.5), respectively. Of the 54 asymptomatic PCR-positive patients, 39 (72.2%) had Ct values >35 and were deemed noninfectious, 11 (20.4%) had Ct values <30, and 4 (7.4%) had Ct values between 30 and 35. Infectious diseases consultation, including review of Ct values, was obtained for 10 asymptomatic PCR-positive patients (18.5%) within 2 days of admission.

Of the 39 asymptomatic patients deemed noninfectious, 10 (25.6%) had follow-up PCR tests within 3 days of admission, and all had Ct values >35. Also, 13 (33.3%) of these patients had antigen tests within 3 days and all were negative. Furthermore, 7 (17.9%) of these patients had COVID-19 >90 days prior to admission (range, 4–12 months). Moreover, 23 (59.0%) had had 1 or more adverse consequences: delays in medical care (N = 13) including cancelation of admissions (N = 8), unnecessary isolation (N = 9) ranging from 2 to 10 days, admission to a double-occupancy room with a roommate with acute COVID-19 (N = 1), and unnecessary COVID-19 treatment (N = 7). Table 1 provides several examples of adverse consequences associated with asymptomatic screening.

Our findings are consistent with those of previous studies suggesting that asymptomatic admission screening could be beneficial in reducing nosocomial transmission of SARS-CoV-2. Admission screening detected 9 presymptomatic patients and 15 asymptomatic patients with Ct values <35, including 11 with...
Ct value <30. Such patients may contribute substantially to transmission, including to roommates in healthcare facilities. However, it is not clear that universal admission screening adds to infection control during patient care. An alternative approach might involve targeted screening of patients being admitted to double-occupancy rooms or to high-risk areas such as oncology wards.

Our findings also highlight the potential for adverse consequences of asymptomatic admission screening using PCR-based assays. 72% of the asymptomatic patients testing positive by PCR were deemed noninfectious based on clinical presentation and Ct values >35. Furthermore, 18% of these patients had prior SARS-CoV-2 infection 4–12 months before admission, probably with persistent positive PCR results. Others likely had undocumented prior infections. Asymptomatic but noninfectious patients experienced a variety of adverse effects, including delays in care and unnecessary isolation and treatment. Although Ct values must be interpreted with caution, our results are consistent with previous reports suggesting that Ct values can be a useful adjunct in evaluation of asymptomatic patients testing positive on admission.1

Acknowledgments.

Financial support. This research was supported by the Department of Veterans’ Affairs.

Conflicts of interest. C.J.D. has received research grants from Clorox, Pfizer, and PDI. All other authors report no conflicts of interest relevant to this article.

References


### Table 1. Examples of Adverse Consequences for Asymptomatic Patients Testing Positive for SARS-CoV-2 on Admission Screening by PCR

<table>
<thead>
<tr>
<th>Reason for Admission</th>
<th>PCR Cycle Threshold</th>
<th>Antigen Result</th>
<th>Adverse Effects of Positive Screen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evaluation for suspected malignancy</td>
<td>37</td>
<td>Negative</td>
<td>Admission canceled; prescribed nirmatrelvir/ritonavir despite bilirubin level 9 mg/dL; admitted after follow-up PCR test negative 2 d later</td>
</tr>
<tr>
<td>Vascular surgery</td>
<td>42</td>
<td>Negative</td>
<td>Admission canceled and surgery delayed 30 d</td>
</tr>
<tr>
<td>Cardiac surgery</td>
<td>41</td>
<td>Negative</td>
<td>Admission canceled and surgery delayed 10 d</td>
</tr>
<tr>
<td>Suicidal ideation</td>
<td>42</td>
<td>Negative</td>
<td>Admission to intensive care for 1 to 1 monitoring for 2 d awaiting follow-up PCR cycle threshold</td>
</tr>
<tr>
<td>Diabetic foot infection</td>
<td>42</td>
<td>Negative</td>
<td>Placed in isolation with a SARS-CoV-2-infected roommate for 3 days until follow-up PCR was negative; treated with remdesivir ×3 d</td>
</tr>
<tr>
<td>Pulmonary embolus</td>
<td>43</td>
<td>ND</td>
<td>Isolated for 2 d until follow-up PCR was negative</td>
</tr>
<tr>
<td>Homeless/Edema</td>
<td>42</td>
<td>Negative</td>
<td>Isolated for 6 days; treated with remdesivir ×2 d, discontinued due to liver enzyme elevation</td>
</tr>
</tbody>
</table>

Note. PCR, polymerase chain reaction; ND, not done; N2, nucleocapsid.

*Cycle threshold for N2 target.*